Rotavirus is the leading cause of dehydrating acute gastroenteritis in infants and young children around the world and continues to infect virtually all infants and children by the age of 5 years, the great majority in the first 2 years of life (14) . Rotavirus infections account for approximately a half-million deaths annually in the developing world. In the United States, where ϳ50 deaths attributable to rotavirus are reported each year, rotavirus infections cause an estimated 50,000 to 70,000 hospitalizations per year.
The rotavirus epidemic season in the United States typically begins in the late autumn in the Southwest and then appears sequentially in other regions extending in a northeasterly direction until peaking in New England in mid-spring. In Philadelphia, rotavirus cases are usually seen first in January and the number of cases typically peaks by March or April, after which cases decrease rapidly until virtually disappearing by the end of June (4) . Multiple rotavirus serotypes usually circulate during a local epidemic. Overall, G1P1A [8] is the most common serotype causing human disease throughout the world, but outbreaks in which G3, G9, or G2 rotaviruses were atypically prominent have been seen in Philadelphia during the last 14 years (4 (16, 17) . The longstanding surveillance system for acute gastroenteritis at The Children's Hospital of Philadelphia (CHOP) provided a unique opportunity to assess the impact of the pentavalent vaccine in actual clinical practice.
MATERIALS AND METHODS
The protocol was approved by the institutional review board at CHOP. Referral patterns have been previously described (6) . Informed consent from legal guardians was not required to procure and process stool specimens already obtained from children with acute gastroenteritis as part of standard clinical practice. If a bulk sample was not available, rectal swabs were only accepted if fecal staining was visible. Based on prior experience, the rotavirus epidemic season in Philadelphia was defined as the 7-month period from 1 December through 30 June of the following year (4). presumably not vaccinated because they were already Ͼ32 weeks old before the vaccine became available (1). In addition, four children Յ2 months of age should have received at most the first dose of vaccine based on current recommendations. Of the five patients (ages 2, 8, 11, 16, and 21 months at the time of their rotavirus gastroenteritis) for whom immunization histories were accessible, the 8-month-old child and 11-month-old child had each received a single dose of rotavirus vaccine and the other three children had not been vaccinated. Overall, 32 (89%) patients were kept overnight in the emergency department holding area (n ϭ 3) or admitted to the hospital (n ϭ 29) for a median duration of 2 days.
RESULTS

Ongoing
In 2007 to 2008, rotavirus cases appeared later than in previous years ( VP7 genotyping of the 36 community isolates in 2007 to 2008 revealed 11 G1, 3 G2, 15 G3, 1 G4, 1 G9, 1 G12, and 4 nontypeable cases (Fig. 4 and Table 1 ). There were no cases caused by the bovine G6 strain used in the pentavalent vaccine during the 2007-2008 season, but one bovine G6 case was identified in 2006 to 2007. Although G3 rotaviruses had not caused a substantial fraction of cases at CHOP since the 1994-1995 season, G3 was the predominant serotype among the 2007-2008 rotavirus cases, accounting for 42% of the community-acquired infections. All of the VP4-typeable cases were P1A [8] , except for one case each of G1P1B [4] and G2P1B [4] . Of the two G2 cases with identifiable VP4 types, one was associated with the typical P1B [4] , whereas the other was associated with P1A [8] , which has only uncommonly been linked to G2 strains. 
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on September 6, 2017 by guest http://cvi.asm.org/ had previously been identified among the community-acquired cases.
DISCUSSION
A pentavalent rotavirus vaccine was licensed in the United States in February 2006 and recommended later in the same month for universal use by the Advisory Committee on Immunization Practices as a three-dose series to be given at 2, 4, and 6 months of age (1) . The formal recommendation for use of the pentavalent rotavirus vaccine warns not to administer any dose of the vaccine to children Ͼ32 weeks old because of a possible age-related risk of intussusception. By the summer of 2007, the Centers for Disease Control and Prevention reported that vaccination rates had approached 50% in five sentinel cities (2, 3) . A public health official in Philadelphia unofficially estimated that the overall coverage rate in the city as of mid-2008 was near 60%, but uptake of the vaccine may vary by [8] ; 14 cases of G3P1A [8] ; 3 cases of (G-nontypeable)P1A [8] ; and 1 case each of G1P1B [4] , G2P1A [8] , G2P1B [4] , G2/QNS (QNS, quantity not sufficient), G3(P-nontypeable), G4P1A [8] , G9P1A [8] , G12P1A [8] , and nontypeable. Genotyping of the 14 nosocomial cases in 2007 to 2008 revealed 2 cases of G2P1B [4] ; 7 cases of G3P1A [8] ; 2 cases of (Gnontypeable)P1A [8] ; and 1 case each of G1P1A [8] , G2(P-nontypeable), and nontypeable. All serotypes causing nosocomial infections appeared earlier in the community. (2) . The theoretical possibility that vaccinated children who subsequently developed symptomatic rotavirus gastroenteritis severe enough to result in a hospital visit might have had falsely negative rotavirus ELISA results due to limited viral replication in the gut seems biologically implausible. Unfortunately, we did not have complete access to the vaccination histories of individual children presenting to CHOP with rotavirus gastroenteritis during the 2007-2008 season, but a third of patients should not have been given a dose of the rotavirus vaccine based on the upper-age restriction; another 11% were too young to have received any more than one dose, if vaccinated at all (8, 10) . None of the five children with rotavirus gastroenteritis whose immunization status could be ascertained had received more than a single dose of the three-dose vaccine series.
Because protection rates appear to have exceeded vaccination rates, some degree of herd immunity (with or without a minor element of contact immunization as the result of shedding by vaccinated children) may have further contributed to the overall effectiveness of the vaccine. Except for a single case over the last 2 years, vaccine strains have not been demonstrated in children with rotavirus gastroenteritis severe enough to be brought to CHOP. A decrease in the number of susceptible children could explain the late appearance of rotavirus cases in 2007 to 2008, observed not only in Philadelphia but throughout the United States (2, 13) . Herd immunity might also be responsible for the absolute reduction of cases in children who were too old to have been vaccinated. Although G1 has usually been the most common serotype identified in children presenting to the hospital with rotavirus gastroenteritis (4), G3 rotaviruses predominated during the 2007-2008 season in the Philadelphia area served by CHOP, causing 15 (47%) of the 32 VP7-typeable community cases. Despite G3 and P1A [8] both being contained in the pentavalent vaccine, the widespread use of the vaccine could have led to the apparent emergence of G3 strains in 2007 to 2008 as well as the associated decline in overall case frequency. Alternatively, the serendipitous appearance of a less contagious and/or less virulent G3 strain independent of the introduction of the vaccine may be responsible for the decline in rotavirus cases presenting to the hospital. However, in the 1994-1995 season (predating the short-lived availability of the tetravalent rhesushuman reassortant rotavirus vaccine [RotaShield; Wyeth, Madison, NJ] during 1998 to 1999), when G3 rotaviruses last played a major role in the Philadelphia epidemic (93% of the typed cases), the timing and total number of community-acquired cases (n ϭ 198) resembled patterns from other years (2) . Continuing surveillance will test whether these trends are chance variation or sustained by expanding vaccine coverage.
Our study is subject to all the limitations of an observational study using historical controls. Unrecognized covariates other than vaccination (such as decreased virulence of circulating rotavirus strains or changing referral patterns at our hospital) and random variation may have been responsible for the results. However, the quantitatively similar observations concurrently reported from another hospital in a different neighborhood of Philadelphia (8) as well as from several other sites across the United States (10-12, 15) support our tentative conclusion that vaccination is the most likely and parsimonious explanation for the declining incidence of rotavirus gastroenteritis at our institution. 
